iOmx
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Fraunhoferstrasse 13, Martinsried/ Munic...Phone Number
+49 89899970900Website
www.iomx.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About iOmx
iOmx Therapeutics, located in Martinsried, Germany, is a biopharmaceutical company focused on developing first-in-class cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iOmx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when iOmx launches new products
Funding: Get notified immidiatlly once iOmx has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if iOmx had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if iOmx has recently received funding, and reach out quickly before it becomes old news!
Check out if iOmx is spiking on competitors!
iOmx, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on iOmx recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at iOmx
Recommended Actions
Reach out to Masked Content who joined iOmx as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
iOmx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
iOmx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about iOmx.
iOmx financials insights
Gather financial insights about iOmx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$44.6M
2021
Series B
$75.4M
iOmx Tech Stack
A closer look at the technologies used by iOmx
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
iOmx News & Media
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
MUNICH, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced that its high-throughput target discovery platform, myeloid iOTargTM, will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023. Further, the company will present new data on its lead product candidate, OMX-0407, in a poster presentationIOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development
DGAP-News: iOmx Therapeutics AG / Key word: Personnel iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development 03.02.2022 / 10:00 The issuer is solely...iOmx Therapeutics Raises EUR 65 million in Series B Round - Yahoo Finance
The financing was co-led by Athos Service GmbH - the Strüngmann family office - and MIG Capital AG, with participation from existing investors Wellington Partners, Sofinnova Partners and M Ventures.The new funds will be invested to advance the company's lead program IMT-07, a SIK3 kinase inhibitor to treat solid tumors, through the first-in-man clinical trial, and to further develop IMT-18, a first-in-class IGSF11-targeting antibody to treat PD-1/PD-L1-resistant tumors.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iOmx
Sign Up For FreeTo access detailed company insights
iOmx Therapeutics, located in Martinsried, Germany, is a biopharmaceutical company focused on developing first-in-class cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells.... Read More
